SpyGlass Pharma, Inc. (SGP) stock

Surgical & Medical Instruments & Apparatus

SpyGlass Pharma, Inc. (SGP) stock: what's happening now, every material event decoded in plain English, P/E and valuation, analyst ratings, and insider buying and selling.

What’s happening with SpyGlass Pharma, Inc.

SpyGlass Pharma, Inc. stock — financials & valuation

AllSight quality score: 58/100 — a percentile rank of SpyGlass Pharma, Inc.’s fundamentals against Manufacturing peers.

SpyGlass Pharma, Inc. (SGP) analyst ratings & price target

Consensus: Buy from 1 analysts (Buy 1).

Average price target: $40.00 (+30.0% vs $30.78); range $37–$44.

Wall Street analyst consensus, shown as context — not an AllSight view.

SpyGlass Pharma, Inc. (SGP) insider trading

Open-market buys: 30 · Open-market sells: 0 · Net: +$483M

Coordinated block · likely financing, not open-market conviction.

Discretionary open-market purchases are the signal; grants, option exercises and Rule 10b5-1 scheduled trades are context, not counted in the balance. Facts only — not a recommendation. Source: SEC Form 4 filings on EDGAR.

SpyGlass Pharma, Inc. news, decoded

SpyGlass Pharma, Inc. (SGP) Stock — News, Financials & Insider Trading
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.